

#### 2052MOBYB12TS FP

Sample ID: 2402APO0584.2787 Strain: Moby Dick Matrix: Plant Type: Flower - Cured Source Batch #: 2052

Apollo Labs 17301 North Perimeter Drive Scottsdale, AZ 85255

Collected: 02/12/2024 03:31 pm

Received: 02/12/2024

Completed: 02/16/2024

Produced:

Batch #: 2052

(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

Client

High Mountain Health, LLC

Lic. # 00000050DCBO00239922

1 of 4



Batch #: 2052 Harvest Date: 01/23/2024		Lot #: Production Date: Production Metho
Sell C	Summary	
CALL IN	Test Batch	

	Production Method: Indoor	
Summary		
Test	Date Tested	Result
Batch		Pass
Cannabinoids	02/14/2024	Complete
Microbials	02/15/2024	Pass
Pesticides	02/13/2024	Pass
Heavy Metals	02/13/2024	Pass

Cannabinoids

Complete

<b>17.4482%</b> Total THC	<lo Total C</lo 	-	21.7053 Total Cannal	(03)	NT Total Terpenes
Analyte LOD	LOQ	Result	Result		9
%	%	%	mg/g		
THCa	0.1000	19.3076	193.076		
Δ9-THC	0.1000	0.5154	5.154		
Δ8-THC	0.1000	ND	ND		
THCV	0.1000	ND	ND		
CBDa	0.1000	<loq< td=""><td><loq< td=""><td></td><td></td></loq<></td></loq<>	<loq< td=""><td></td><td></td></loq<>		
CBD	0.1000	ND	ND		
CBDVa	0.1000	ND	ND		
CBDV	0.1000	ND	ND		
CBN	0.1000	ND	ND		
CBGa	0.1000	1.7544	17.544		
CBG	0.1000	0.1280	1.280		
CBC	0.1000	ND	ND		
Total THC		17.4482	174.4820		
Total CBD		<loq< td=""><td><loq< td=""><td></td><td></td></loq<></td></loq<>	<loq< td=""><td></td><td></td></loq<>		
Total		21.7053	217.053		

#### Date Tested: 02/14/2024 07:00 am



product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

# LABS

### 2052MOBYB12TS FP

Sample ID: 2402APO0584.2787 Strain: Moby Dick Matrix: Plant Type: Flower - Cured Source Batch #: 2052

#### Apollo Labs 17301 North Perimeter Drive Scottsdale, AZ 85255

(602) 767-7600 http://www.apollolabscorp.com Lic# 0000013LCRK62049775

2 of 4

Pass

Produced: Collected: 02/12/2024 03:31 pm Received: 02/12/2024 Completed: 02/16/2024 Batch #: 2052 Harvest Date: 01/23/2024

Client High Mountain Health, LLC Lic. # 00000050DCBO00239922

Lot #: Production Date: Production Method: Indoor

#### Pesticides

Analyte	LOQ	Limit	Mass	Q	Status	Analyte	LOQ	Limit	Mass	Q	Status
	PPM	PPM	PPM				PPM	PPM	PPM		
Abamectin	0.2500	0.5000	ND		Pass	Hexythiazox	0.5000	1.0000	ND		Pass
Acephate	0.2000	0.4000	ND		Pass	Imazalil	0.1000	0.2000	ND		Pass
Acetamiprid	0.1000	0.2000	ND		Pass	Imidacloprid	0.2000	0.4000	ND	M1	Pass
Aldicarb	0.2000	0.4000	ND		Pass	Kresoxim Methyl	0.2000	0.4000	ND		Pass
Azoxystrobin	0.1000	0.2000	ND		Pass	Malathion	0.1000	0.2000	ND		Pass
Bifenazate	0.1000	0.2000	ND	M1	Pass	Metalaxyl	0.1000	0.2000	ND		Pass
Bifenthrin	0.1000	0.2000	ND		Pass	Methiocarb	0.1000	0.2000	ND		Pass
Boscalid	0.2000	0.4000	ND		Pass	Methomyl	0.2000	0.4000	ND		Pass
Carbaryl	0.1000	0.2000	ND		Pass	Myclobutanil	0.1000	0.2000	ND		Pass
Carbofuran	0.1000	0.2000	ND		Pass	Naled	0.2500	0.5000	ND		Pass
Chlorantraniliprole	0.1000	0.2000	ND		Pass	Oxamyl	0.5000	1.0000	ND		Pass
Chlorfenapyr	0.5000	1.0000	ND		Pass	Paclobutrazol	0.2000	0.4000	ND		Pass
Chlorpyrifos	0.1000	0.2000	ND	M2	Pass	Permethrins	0.1000	0.2000	ND	M2	Pass
Clofentezine	0.1000	0.2000	ND	M2	Pass	Phosmet	0.1000	0.2000	ND		Pass
Cyfluthrin	0.5000	1.0000	ND		Pass	Piperonyl	1.0000	2.0000	ND		Pass
Cypermethrin	0.5000	1.0000	ND		Pass	Butoxide					
Daminozide	0.5000	1.0000	ND		Pass	Prallethrin	0.1000	0.2000	ND		Pass
Diazinon	0.1000	0.2000	ND		Pass	Propiconazole	0.2000	0.4000	ND		Pass
Dichlorvos	0.0500	0.1000	ND		Pass	Propoxur	0.1000	0.2000	ND	R1	Pass
Dimethoate	0.1000	0.2000	ND		Pass	Pyrethrins	0.5000	1.0000	ND	M2	Pass
Ethoprophos	0.1000	0.2000	ND		Pass	Pyridaben	0.1000	0.2000	ND		Pass
Etofenprox	0.2000	0.4000	ND	M2	Pass	Spinosad	0.1000	0.2000	ND	M1	Pass
Etoxazole	0.1000	0.2000	ND		Pass	Spiromesifen	0.1000	0.2000	ND		Pass
Fenoxycarb	0.1000	0.2000	ND		Pass	Spirotetramat	0.1000	0.2000	ND		Pass
Fenpyroximate	0.2000	0.4000	ND		Pass	Spiroxamine	0.2000	0.4000	ND	M1	Pass
Fipronil	0.2000	0.4000	ND		Pass	Tebuconazole	0.2000	0.4000	ND		Pass
Flonicamid	0.5000	1.0000	ND		Pass	Thiacloprid	0.1000	0.2000	ND		Pass
Fludioxonil	0.2000	0.4000	ND		Pass	Thiamethoxam	0.1000	0.2000	ND		Pass
						Trifloxystrobin	0.1000	0.2000	ND		Pass

Date Tested: 02/13/2024 07:00 am



product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.



2 Sa Sti M Ty Sc

Apollo Labs 17301 North Perimeter Drive Scottsdale, AZ 85255

(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

3 of 4

Pass

2052MOBYB12TS FP	
ample ID: 2402APO0584.2787 train: Moby Dick	Produced: Collected: 02/12/2024
1atrix: Plant ype: Flower - Cured ource Batch #: 2052	Received: 02/12/2024 Completed: 02/16/202 Batch #: 2052 Harvest Date: 01/23/2
Microbials	

4 03:31 pm 24 2024

Client High Mountain Health, LLC Lic. # 0000050DCB000239922

Lot #: Production Date: Production Method: Indoor

#### Μ

\_

		Status	Q
ot Detected in 1g	ND	Pass	
ot Detected in 1g	ND	Pass	
ot Detected in 1g	ND	Pass	
(	ot Detected in 1g ot Detected in 1g ot Detected in 1g	ot Detected in 1g ND	ot Detected in 1g ND Pass

LOQ	Limit	Result	Status	Q
CFU/g	CFU/g	CFU/g		
10.0	100.0	< 10 CFU/g	Pass	
	CFU/g	CFU/g CFU/g	CFU/g CFU/g CFU/g	CFU/g CFU/g <b>CFU/</b> g

#### Date Tested: 02/15/2024 12:00 am

Mycotoxins					No	ot Tested
Analyte	LOD	LOQ	Limit	Units	Status	Q

Date Tested:

#### **Heavy Metals** Pass LOQ Analyte LOD Limit Units Status Q PPM PPM PPM PPM 0.4000 Arsenic 0.0660 0.1330 ND Pass Cadmium 0.0660 0.1330 0.4000 ND Pass Lead 0.1660 0.3330 1.0000 ND Pass 0.0330 0.0660 0.2000 ND Pass Mercury

Date Tested: 02/13/2024 07:00 am

Bryant Kearl Lab Director 02/16/2024	Confident LIMS All Rights Reserved coa.support@confidentlims.com (866) 506-5866 www.confidentlims.com	confident
a motor vehicle or operate heavy machinery. Marijuana smoke contains carcinogens ar a and the unborn child. Using marijuana during pregnancy could cause birth defects or c		ion, heart attack,

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.

# 

### 2052MOBYB12TS FP

Sample ID: 2402APO0584.2787 Strain: Moby Dick Matrix: Plant Type: Flower - Cured Source Batch #: 2052 Apollo Labs 17301 North Perimeter Drive Scottsdale, AZ 85255

(602) 767-7600 http://www.apollolabscorp.com Lic# 00000013LCRK62049775

4 of 4

Produced: Collected: 02/12/2024 03:31 pm Received: 02/12/2024 Completed: 02/16/2024 Batch #: 2052 Harvest Date: 01/23/2024

Client High Mountain Health, LLC Lic. # 0000050DCB000239922

Lot #: Production Date: Production Method: Indoor

## **Qualifiers** Definitions

Qualifier Notation	Qualifier Description
11	The relative intensity of a characteristic ion in a sample analyte exceeded the acceptance criteria in subsection (L)(1) with respect to the reference spectra, indicating interference
L1	When testing for pesticides, fungicides, herbicides, growth regulators, heavy metals, or residual solvents, the percent recovery of a laboratory control sample is greater than the acceptance limits in subsection (K)(2)(c), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
M1	The recovery from the matrix spike in subsection (K)(4) was: a. High, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M2	The recovery from the matrix spike in subsection (K)(4) was: b. Low, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
M3	The recovery from the matrix spike in subsection (K)(4) was: c. Unusable because the analyte concentration was disproportionate to the spike level, but the recovery from the laboratory control sample in subsection (K)(2) was within acceptance criteria
R1	The relative percent difference for the laboratory control sample and duplicate exceeded the limit in subsection $(K)(3)$ , but the recovery in subsection $(K)(2)$ was within acceptance criteria
V1	The recovery from continuing calibration verification standards exceeded the acceptance limits in subsection (J) (1)(b), but the sample's target analytes were not detected above the maximum allowable concentrations in Table 3.1 for the analytes in the sample
Q2	The sample is heterogeneous, and sample homogeneity could not be readily achieved using routine laboratory practices – Used to denote that the sample as-received could not be fully pre-homogenized in packaging prior to microbiology analysis
Q3	Testing result is for informational purposes only and cannot be used to satisfy dispensary testing requirements in R9-17-317.01(A) or labeling requirements in R9-17-317

## Notes and Addenda:

	Bryant Kearl Lab Director 02/16/2024	Confident LIMS All Rights Reserved coa.support@confidentlims.com (866) 506-5866 www.confidentlims.com	confident
ARIZONA DEPARTMENT OF HEALTH SERVICES' WARNING: Marijuana use can be addictive and can impair an individual's ability to drive a motor vehicle and lung infection. Marijuana use may affect the health of a pregnant woman and the unborn KEFE OLIT OF BERACH OF CHILDREN			ion, heart attack,

The product associated with the COA has been tested by Apollo Labs using validated state certified testing methodologies as required by Arizona state law. Values reported herein relate only to the specific sample of product submitted by Client for testing. Apollo Labs makes no claims as to the efficacy, safety or other risks associated with any detected or non-detected levels of any compounds reported herein. This Certificate shall not be reproduced except in full, without the written approval of Apollo Labs.